āĻšā§āĻŽAMLX âĸ NASDAQ
add
Amylyx Pharmaceuticals Inc
ā§§ā§Ē.ā§¯ā§Ē$
ā§¨ā§Ŧ āĻāĻžāĻ¨ā§, ā§Š:ā§§ā§Ž:ā§Šā§¨ PM GMT -ā§Ģ · USD · NASDAQ · āĻĄāĻŋāĻ¸āĻā§āĻ˛ā§āĻŽāĻžāĻ°
āĻ¸ā§āĻāĻāĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ āĻ¯ā§āĻā§āĻ¤āĻ°āĻžāĻˇā§āĻā§āĻ°-āĻ āĻ¤āĻžāĻ˛āĻŋāĻāĻžāĻā§āĻā§āĻ¤ āĻ¸āĻŋāĻāĻŋāĻāĻ°āĻŋāĻāĻŋ
āĻāĻžāĻ˛ āĻļā§āĻˇ āĻ¯ā§ āĻĻāĻžāĻŽā§ āĻāĻŋāĻ˛
ā§§ā§Ģ.ā§ā§Ŧ$
āĻ¸āĻžāĻ°āĻž āĻĻāĻŋāĻ¨ā§āĻ° āĻā§āĻ°ā§āĻĄāĻŋāĻā§ā§ āĻ¸ā§āĻāĻā§āĻ° āĻĻāĻžāĻŽā§āĻ° āĻāĻ āĻž āĻ¨āĻžāĻŽāĻžāĻ° āĻ°ā§āĻā§āĻ
ā§§ā§Ē.ā§¯ā§¨$ - ā§§ā§Ģ.ā§Ŧā§¨$
āĻ¸āĻžāĻ°āĻž āĻŦāĻāĻ°ā§āĻ° āĻ°ā§āĻā§āĻ
ā§¨.ā§Ŧā§§$ - ā§§ā§.ā§Ēā§¯$
āĻŽāĻžāĻ°ā§āĻā§āĻ āĻā§āĻ¯āĻžāĻĒ
ā§§ā§Ŧā§Ē.ā§§ā§ŠÂ āĻā§ USD
āĻāĻĄāĻŧ āĻāĻ˛āĻŋāĻāĻŽ
ā§§ā§Ž.ā§Žā§Ģ āĻ˛āĻž
P/E āĻ
āĻ¨ā§āĻĒāĻžāĻ¤
-
āĻ˛āĻā§āĻ¯āĻžāĻāĻļ āĻĒā§āĻ°āĻĻāĻžāĻ¨
-
āĻĒā§āĻ°āĻžāĻāĻŽāĻžāĻ°āĻŋ āĻāĻā§āĻ¸āĻā§āĻā§āĻ
NASDAQ
āĻāĻŦāĻ°ā§ āĻ°ā§ā§āĻā§
āĻĢāĻžāĻāĻ¨āĻžāĻ¨ā§āĻ¸āĻŋā§āĻžāĻ˛ āĻĒāĻžāĻ°āĻĢāĻ°ā§āĻŽā§āĻ¯āĻžāĻ¨ā§āĻ¸
āĻā§ā§āĻ° āĻ¸ā§āĻā§āĻāĻŽā§āĻ¨ā§āĻ
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ
| (USD) | āĻ¸ā§āĻĒ ā§¨ā§Ļā§¨ā§Ģinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | â | â |
āĻŦā§āĻ¯āĻŦāĻ¸āĻž āĻāĻžāĻ˛āĻžāĻ¨ā§āĻ° āĻāĻ°āĻ | ā§§.ā§Ŧā§¨Â āĻā§ | -ā§¯.ā§¨ā§¯% |
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§Š.ā§Ēā§Ē āĻā§ | ā§Ģā§¨.ā§ā§Ļ% |
āĻ¨ā§āĻ āĻĒā§āĻ°āĻĢāĻŋāĻ āĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ | â | â |
āĻļā§ā§āĻžāĻ° āĻĒā§āĻ°āĻ¤āĻŋ āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | -ā§Ļ.ā§Šā§ | ā§Ŧā§Ģ.ā§Ēā§¨% |
EBITDA | -ā§Š.ā§Ģā§¯Â āĻā§ | ā§Ž.ā§Ēā§¯% |
āĻĒā§āĻ°āĻ¯ā§āĻā§āĻ¯ āĻā§āĻ¯āĻžāĻā§āĻ¸ā§āĻ° āĻšāĻžāĻ° | â | â |
āĻŦā§āĻ¯āĻžāĻ˛ā§āĻ¨ā§āĻ¸ āĻļāĻŋāĻ
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
| (USD) | āĻ¸ā§āĻĒ ā§¨ā§Ļā§¨ā§Ģinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻā§āĻ¯āĻžāĻļ āĻ āĻāĻŽ āĻ¸āĻŽā§ā§āĻ° āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ | ā§Šā§Ē.ā§Ēā§Ļ āĻā§ | ā§Ēā§Ŧ.ā§ā§Ŧ% |
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ | ā§Šā§Ŧ.ā§¨ā§Â āĻā§ | ā§Ēā§Ē.ā§Ŧā§Ž% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§Š.ā§Ļā§Â āĻā§ | -ā§Ēā§Š.ā§Ŧā§Ļ% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§Šā§Š.ā§¨ā§Ļ āĻā§ | â |
āĻāĻāĻāĻ¸ā§āĻā§āĻ¯āĻžāĻ¨ā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāĻ° | ā§§ā§Ļ.ā§¯ā§ŽÂ āĻā§ | â |
āĻĒā§āĻ°āĻžāĻāĻ¸ āĻā§ āĻŦā§āĻ āĻ°ā§āĻļāĻŋāĻ | ā§Ģ.ā§¨ā§¨ | â |
āĻ¸āĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | -ā§Šā§¨.ā§Šā§¨% | â |
āĻŽā§āĻ˛āĻ§āĻ¨ āĻĨā§āĻā§ āĻā§ | -ā§Šā§Ģ.ā§¨ā§Ļ% | â |
āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨
| (USD) | āĻ¸ā§āĻĒ ā§¨ā§Ļā§¨ā§Ģinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§Š.ā§Ēā§Ē āĻā§ | ā§Ģā§¨.ā§ā§Ļ% |
āĻ
āĻĒāĻžāĻ°ā§āĻļāĻ¨ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āĻ¯āĻžāĻļ | -ā§Š.ā§Ļā§Ē āĻā§ | ā§¨ā§Ŧ.ā§¯ā§Ģ% |
āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | ā§Ģā§¨.ā§Šā§Ŧ āĻ˛āĻž | -ā§Žā§Ŧ.ā§Ģā§§% |
āĻĢāĻžāĻāĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¸āĻŋāĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | ā§§ā§¯.ā§§ā§Ŧ āĻā§ | ā§¨ā§Šā§¯,ā§Ēā§Ļā§.ā§Ģā§Ļ% |
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ | ā§§ā§Ŧ.ā§Ŧā§Ŧ āĻā§ | ā§Ŧ,ā§¯ā§Šā§Ē.ā§Ģā§Ļ% |
āĻĢā§āĻ°āĻŋ āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§ | -ā§§.ā§Ēā§Ŧ āĻā§ | ā§ā§Ŧ.ā§¯ā§¯% |
āĻ¸āĻŽā§āĻĒāĻ°ā§āĻā§
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāĻ¤ āĻšā§ā§āĻā§
ā§¨ā§Ļā§§ā§Š
āĻā§ā§āĻŦāĻ¸āĻžāĻāĻ
āĻāĻ°ā§āĻŽāĻāĻžāĻ°ā§
ā§§ā§¨ā§Š
